Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
复制标题
来自具有配对肝转移的结直肠癌患者的类器官揭示了肿瘤异质性并预测对化疗的反应
DOI：
10.1002/advs.202204097
复制
发表时间：
2022-11
期刊：
影响因子：
--
通讯作者：
Hua G
中科院分区：
文献类型：
--
作者：
Mo S;Tang P;Luo W;Zhang L;Li Y;Hu X;Ma X;Chen Y;Bao Y;He X;Fu G;Xu X;Rao X;Li X;Guan R;Chen S;Deng Y;Lv T;Mu P;Zheng Q;Wang S;Liu F;Li Y;Sheng W;Huang D;Hu C;Gao J;Zhang Z;Cai S;Clevers H;Peng J;Hua G
目前尚无有效的方法预测结直肠癌肝转移患者的化疗疗效和术后预后。患者来源的有机化合物(PDO)已成为一种重要的临床前模型。在这里，成功地构建了一个含有50个来自原发肿瘤和成对肝转移灶的CRLM有机物的活生物库。从多个组学水平(组织病理学、基因组、转录组和单细胞测序)对CRLM PDO进行了全面的分析，证实了这个用于CRLM的有机平台可以捕捉患者内部和患者之间的异质性。体外药敏数据揭示了PDOS在预测CRLM患者化疗疗效(FOLFOX或FOLFIRI)和临床预后方面的潜在应用价值。综上所述，CRLm PDO可以用于提供个性化医疗的潜在应用。患者衍生有机物(PDO)的活生物库来自原发结直肠癌和配对的肝转移病变，它捕获了患者内部和患者之间的分子指纹异质性。体外测定的PDO化疗敏感性可作为临床化疗疗效的预测工具，指导结直肠癌肝转移患者的精确治疗策略的制定。
There is no effective method to predict chemotherapy response and postoperative prognosis of colorectal cancer liver metastasis (CRLM) patients. Patient‐derived organoid (PDO) has become an important preclinical model. Herein, a living biobank with 50 CRLM organoids derived from primary tumors and paired liver metastatic lesions is successfully constructed. CRLM PDOs from the multiomics levels (histopathology, genome, transcriptome and single‐cell sequencing) are comprehensively analyzed and confirmed that this organoid platform for CRLM could capture intra‐ and interpatient heterogeneity. The chemosensitivity data in vitro reveal the potential value of clinical application for PDOs to predict chemotherapy response (FOLFOX or FOLFIRI) and clinical prognosis of CRLM patients. Taken together, CRLM PDOs can be utilized to deliver a potential application for personalized medicine. A living biobank of patient‐derived organoid (PDO) is derived from primary colorectal cancer and paired liver metastatic lesions, which captures intra‐ and interpatient molecular fingerprint heterogeneity. PDO chemosensitivity measured in vitro may be used as a predictive tool for clinical chemotherapeutic efficacy, and guide the formulation of precise treatment strategies for colorectal cancer patients with liver metastases.
登录
查看更多内容
影响因子：
64.5
作者：
Lee SH;Hu W;Matulay JT;Silva MV;Owczarek TB;Kim K;Chua CW;Barlow LJ;Kandoth C;Williams AB;Bergren SK;Pietzak EJ;Anderson CB;Benson MC;Coleman JA;Taylor BS;Abate-Shen C;McKiernan JM;Al-Ahmadie H;Solit DB;Shen MM
通讯作者：
Shen MM
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
16.6
作者：
Ishaque N;Abba ML;Hauser C;Patil N;Paramasivam N;Huebschmann D;Leupold JH;Balasubramanian GP;Kleinheinz K;Toprak UH;Hutter B;Benner A;Shavinskaya A;Zhou C;Gu Z;Kerssemakers J;Marx A;Moniuszko M;Kozlowski M;Reszec J;Niklinski J;Eils J;Schlesner M;Eils R;Brors B;Allgayer H
通讯作者：
Allgayer H
影响因子：
64.5
作者：
Gao D;Vela I;Sboner A;Iaquinta PJ;Karthaus WR;Gopalan A;Dowling C;Wanjala JN;Undvall EA;Arora VK;Wongvipat J;Kossai M;Ramazanoglu S;Barboza LP;Di W;Cao Z;Zhang QF;Sirota I;Ran L;MacDonald TY;Beltran H;Mosquera JM;Touijer KA;Scardino PT;Laudone VP;Curtis KR;Rathkopf DE;Morris MJ;Danila DC;Slovin SF;Solomon SB;Eastham JA;Chi P;Carver B;Rubin MA;Scher HI;Clevers H;Sawyers CL;Chen Y
通讯作者：
Chen Y
影响因子：
82.9
作者：
Kopper, Oded;de Witte, Chris J.;Clevers, Hans
通讯作者：
Clevers, Hans